Appropriate dosing of NEUPOGEN® helps reduce the incidence of febrile neutropenia

NEUPOGEN® used for ≥ 7 days had a lower incidence of febrile neutropenia compared with dosing of < 7 days1

Study design: Data obtained through review of patient medical records for the Oncology Practice Pattern Study at 12 sites between 1991 and 1999. Study included patients (n = 170) with intermediate-grade non-Hodgkin lymphoma treated with first-line CHOP-21 chemotherapy and receiving primary or secondary prophylaxis with NEUPOGEN®. The group of patients who received < 7 days of NEUPOGEN® had 73 cycles of CHOP-21; the group who received ≥ 7 days of NEUPOGEN® had 579 cycles of CHOP-21.1

Dosage in Patients with Cancer Receiving Myelosuppressive Chemotherapy
NEUPOGEN® is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.2

Duration of administration2

  • Up to 2 weeks, until the ANC has reached 10,000/mm3 following expected chemotherapy-induced neutrophil nadir
  • Discontinue NEUPOGEN® if the ANC surpasses 10,000/mm3 after the expected nadir

Recommended dosing and administration2

  • Starting dose of 5 mcg/kg/day administered as single daily injection by SC bolus, short IV infusion, or continuous SC or IV infusion
  • Administer NEUPOGEN® at least 24 hours after chemotherapy, and daily for up to 2 weeks or until ANC has reached 10,000/mm3 following the expected chemotherapy-induced neutrophil nadir
  • Discontinue if ANC surpasses 10,000/mm3 after expected nadir

NEUPOGEN® is available in 300-mg or 480-mg single-dose vials and single-dose prefilled syringes (single and multipacks)2

Dosage in Patients Following Induction and/or Consolidation Chemotherapy for AML
NEUPOGEN® is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with AML.2

Recommended dosing and administration2

  • Starting dosage of 5 mcg/kg/day‚ administered as a single daily injection by subcutaneous injection‚ by short intravenous infusion (15 to 30 minutes)‚ or by continuous intravenous infusion
  • Obtain a CBC and platelet count before instituting therapy and monitor twice weekly during therapy
  • Consider dose escalation in increments of 5 mcg/kg for each chemotherapy cycle‚ according to the duration and severity of ANC nadir
  • Recommend stopping NEUPOGEN® if ANC surpasses 10‚000/mm3
  • Administer ≥ 24 hours after chemotherapy; do not administer within the 24-hour period prior to chemotherapy
  • Administer daily for up to 2 weeks or until the ANC has reached 10‚000/mm3 following the expected chemotherapy-induced neutrophil nadir

NEUPOGEN® is available in 300-mg or 480-mg single-dose vials and single-dose prefilled syringes (single and multipacks)2

Dosage in Patients with Cancer Undergoing Bone Marrow Transplantation
NEUPOGEN® is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae (eg, febrile neutropenia) in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation.2

Recommended dosing and administration2

  • 10 mcg/kg/day given as an intravenous infusion no longer than 24 hours
  • Administer the first dose ≥ 24 hours after chemotherapy and ≥ 24 hours after bone marrow infusion
  • Monitor CBCs and platelet counts frequently following marrow transplantation
  • Titrate against the neutrophil response as follows:
    • When ANC > 1000/mm3 for 3 consecutive days, reduce to 5 mcg/kg/day*
    • Then, if ANC remains > 1000/mm3 for 3 more consecutive days, discontinue NEUPOGEN®
    • Then, if ANC decreases to <1000/mm3, resume at 5 mcg/kg/day
  • If ANC decreases to < 1000/mm3 at any time during 5 mcg/kg/day administration, increase to 10 mcg/kg/day, then follow titration steps above.

NEUPOGEN® is available in 300-mg or 480-mg single-dose vials and single-dose prefilled syringes (single and multipacks)2

Dosage in Patients Undergoing Autologous Peripheral Blood Progenitor Cell Collection and Therapy
NEUPOGEN® is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis.2

Recommended dosing and administration2

  • 10 mcg/kg/day given by subcutaneous injection
  • Administer for ≥ 4 days before the first leukapheresis procedure and continue until the last leukapheresis
  • Administration of NEUPOGEN® for 6 to 7 days with leukaphereses on days 5‚ 6‚ and 7 was found to be safe and effective
  • Monitor neutrophil counts after 4 days of NEUPOGEN®‚ and discontinue if the WBC count rises to > 100‚000/mm3

NEUPOGEN® is available in 300-mg or 480-mg single-dose vials and single-dose prefilled syringes (single and multipacks)2

Dosage in Patients with Severe Chronic Neutropenia
NEUPOGEN® is indicated for chronic administration to reduce the incidence and duration of sequelae of severe neutropenia (eg‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia.2

Prior to starting NEUPOGEN® in patients with suspected chronic neutropenia, confirm the diagnosis of SCN by evaluating serial CBCs with differential and platelet counts‚ and evaluating bone marrow morphology and karyotype. The use of NEUPOGEN® prior to confirmation of a correct diagnosis of SCN may impair diagnostic efforts and may thus impair or delay evaluation and treatment of an underlying condition other than SCN‚ causing the neutropenia.2

Duration of administration2

  • Starting dosage of:
    • 6 mcg/kg as a twice daily subcutaneous injection (congenital neutropenia)
    • 5 mcg/kg as a single daily subcutaneous injection (idiopathic or cyclic neutropenia)
  • Chronic daily administration is required to maintain clinical benefit. Individualize dosage based on clinical course and ANC
  • In the SCN postmarketing surveillance study, the reported median daily doses were: 6 mcg/kg (congenital neutropenia),* 2.1 mcg/kg (cyclic neutropenia), and 1.2 mcg/kg (idiopathic neutropenia)*
  • During initial 4 weeks of therapy and during 2 weeks following any dosage adjustment‚ monitor CBCs with differential and platelet counts
  • Once clinically stable‚ monitor CBCs with differential and platelet counts monthly during the first year of treatment. Thereafter, if patient is clinically stable, less frequent monitoring is recommended

*In rare instances, patients with congenital neutropenia have required doses of NEUPOGEN® greater than or equal to 100 mcg/kg/day.

NEUPOGEN® is available in 300-mg or 480-mg single-dose vials and single-dose prefilled syringes (single and multipacks)2

AML = acute myeloid leukemia; ANC = absolute neutrophil count; CBC = complete blood count; CHOP-21 = cyclophosphamide, doxorubicin, vincristine, and prednisone in 21-day cycles; G-CSF = granulocyte-colony stimulating factor; IV = intravenous; SC = subcutaneous; SCN = severe chronic neutropenia; WBC = white blood cell.

SingleJect® Prefilled Syringes2
Pack quantityNDCDescriptionBundle quantity
Carton of 1 prefilled syringe55513-924-91300 mcg/0.5 mL in a single-dose prefilled syringe4 packs
Carton of 1 prefilled syringe55513-209-91480 mcg/0.8 mL in a single-dose prefilled syringe4 packs
Carton of 10 prefilled syringes55513-924-10, 55513-924-20300 mcg/0.5 mL in a single-dose prefilled syringeN/A
Carton of 10 prefilled syringes55513-209-10, 55513-209-20480 mcg/0.8 mL in a single-dose prefilled syringeN/A
Vials2
Pack quantityNDCDescriptionBundle quantity
Carton of 10 vials55513-530-10, 55513-530-20300 mcg/mL
single-dose vial4 packs
Carton of 10 vials55513-546-10, 55513-546-20480 mcg/1.6 mL (300 mcg/mL)
single-dose vial4 packs

*Minimum order of 4 single packs.

CHOP-21 = cyclophosphamide, doxorubicin, vincristine, and prednisone in 21-day cycles.

Important Safety Information and Indications

Contraindication

  • NEUPOGEN® is contraindicated in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors (G-CSFs), such as filgrastim or pegfilgrastim

Splenic Rupture

  • Splenic rupture, including fatal cases, can occur following the administration of NEUPOGEN® 
  • Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture

Acute Respiratory Distress Syndrome (ARDS)

  • ARDS has been reported in patients receiving NEUPOGEN®
  • Evaluate patients who develop fever and lung infiltrates or respiratory distress for ARDS
  • Discontinue NEUPOGEN® in patients with ARDS

Serious Allergic Reactions

  • Serious allergic reactions, including anaphylaxis, have been reported in patients receiving NEUPOGEN® 
  • Majority of reported events occurred upon initial exposure
  • Provide symptomatic treatment for allergic reactions
  • Allergic reactions, including anaphylaxis, in patients receiving NEUPOGEN® can recur within days after the discontinuation of initial anti-allergic treatment
  • Permanently discontinue NEUPOGEN® in patients with serious allergic reactions

Sickle Cell Disorders

  • Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving filgrastim products
  • Discontinue NEUPOGEN® if sickle cell crisis occurs 

Glomerulonephritis

  • Has occurred in patients receiving NEUPOGEN® 
  • Diagnoses were based on azotemia, hematuria, proteinuria, and renal biopsy
  • Generally, events resolved after dose reduction or discontinuation of NEUPOGEN®
  • If causality is likely, consider dose-reduction or interruption of NEUPOGEN® 

Alveolar Hemorrhage and Hemoptysis

  • Alveolar hemorrhage, manifesting as pulmonary infiltrates and hemoptysis requiring hospitalization, have been reported in NEUPOGEN®-treated healthy donors undergoing peripheral blood progenitor cell (PBPC) collection mobilization
  • Hemoptysis resolved with discontinuation of NEUPOGEN®
  • The use of NEUPOGEN® for PBPC mobilization in healthy donors is not an approved indication 

Capillary Leak Syndrome (CLS)

  • CLS has been reported after G-CSF administration, including NEUPOGEN® 
  • Characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration
  • Episodes vary in frequency, severity, and may be life-threatening if treatment is delayed 
  • Patients with symptoms should be closely monitored and receive standard symptomatic treatment, which may include the need for intensive care

Myelodysplastic Syndrome and Acute Myeloid Leukemia (AML)

Patients with Severe Chronic Neutropenia

  • Confirm the diagnosis of SCN before initiating NEUPOGEN® therapy
  • MDS and AML have been reported to occur in the natural history of congenital neutropenia without cytokine therapy 
  • Cytogenetic abnormalities, transformation to MDS, and AML have also been observed in patients treated with NEUPOGEN® for SCN
  • Based on available data including a postmarketing surveillance study, the risk of developing MDS and AML appears to be confined to the subset of patients with congenital neutropenia.
  • Abnormal cytogenetics and MDS have been associated with the eventual development of myeloid leukemia 
  • The effect of NEUPOGEN® on the development of abnormal cytogenetics and the effect of continued NEUPOGEN® administration in patients with abnormal cytogenetics or MDS are unknown. Monitor patients for signs and symptoms of MDS/AML in these settings. 
  • If a patient with SCN develops abnormal cytogenetics or myelodysplasia‚ the risks and benefits of continuing NEUPOGEN® should be carefully considered 

Patients with Breast and Lung Cancer

  • MDS and AML have been associated with the use of NEUPOGEN® in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer. Monitor patients for signs and symptoms of MDS/AML in these settings. 

Thrombocytopenia

  • Thrombocytopenia has been reported in patients receiving NEUPOGEN® 
  • Monitor platelet counts 

Leukocytosis

Patients with Cancer Receiving Myelosuppressive Chemotherapy:

  • White blood cell counts ≥ 100,000/mm3 were observed in about 2% of patients who received NEUPOGEN® at dosages > 5 mcg/kg/day
  • Discontinue NEUPOGEN® if the absolute neutrophil count (ANC) surpasses 10,000/mm3 after the chemotherapy-induced ANC nadir has occurred
  • Monitor CBCs at least twice weekly
  • Dosages of NEUPOGEN® that increase the ANC beyond 10,000/mm3 may not result in any additional clinical benefit
  • Discontinuation of NEUPOGEN® therapy usually resulted in a 50% decrease in circulating neutrophils within 1 to 2 days, with a return to pretreatment levels in 1 to 7 days 

Peripheral Blood Progenitor Cell Collection and Therapy (PBPC):

  • Discontinue NEUPOGEN® if the leukocyte count rises to > 100,000/mm3

Cutaneous Vasculitis

  • Moderate or severe cases of cutaneous vasculitis have been reported in patients treated with NEUPOGEN® 
  • Most reports involved patients with severe chronic neutropenia receiving long-term NEUPOGEN® therapy
  • Hold NEUPOGEN® therapy in patients with cutaneous vasculitis 
  • NEUPOGEN® may be started at a reduced dose when the symptoms resolve and the ANC has decreased 

Potential Effect on Malignant Cells

  • G-CSF receptor has also been found on tumor cell lines 
  • The possibility that NEUPOGEN® acts as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, cannot be excluded
  • The safety of filgrastim in chronic myeloid leukemia (CML) and myelodysplasia has not been established 
  • When NEUPOGEN® is used to mobilize PBPC, tumor cells may be released from the marrow and subsequently collected in the leukapheresis product 
  • The effect on reinfusion of tumor cells has not been well studied, and the limited data available are inconclusive 

Simultaneous Use with Chemotherapy and Radiation Not Recommended

  • The safety and efficacy of NEUPOGEN® given simultaneously with chemotherapy have not been established 
  • Do not use NEUPOGEN® 24 hours before or after administration of chemotherapy 
  • The safety and efficacy of NEUPOGEN® have not been evaluated in patients receiving concurrent radiation therapy 
  • Avoid the simultaneous use of NEUPOGEN® with chemotherapy and radiation therapy 

Nuclear Imaging

  • Increased hematopoietic activity of the bone marrow has been associated with transient positive bone-imaging changes 
  • Consider when interpreting bone-imaging results

Large and Medium Vessel Arteritis

  • Serious large and medium vessel arteritis, including aortitis, has been reported in patients receiving NEUPOGEN® 
  • It may occur as early as the first week after start of therapy 
  • Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, headache, neck pain, and increased inflammatory markers (e.g., c-reactive protein and white blood cell count) 
  • Consider arteritis in patients who develop these signs and symptoms without known etiology
  • Consider appropriate clinical management and discontinue NEUPOGEN® as needed if arteritis is suspected 

The most common adverse reactions in patients:

  • with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs are anemia, constipation, diarrhea, oral pain, vomiting, asthenia, malaise, edema peripheral, hemoglobin decreased, decreased appetite, oropharyngeal pain, and alopecia
  • with AML are epistaxis, back pain, pain in extremity, erythema, rash maculo-papular, diarrhea, constipation, and transfusion reaction 
  • with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by BMT are rash, hypersensitivity, thrombocytopenia, anemia, hypertension, sepsis, bronchitis, and insomnia 
  • undergoing peripheral blood progenitor cell mobilization and collection are bone pain, pyrexia, increased blood alkaline phosphatase, and headache 
  • with severe chronic neutropenia are arthralgia, bone pain, back pain, muscle spasms, musculoskeletal pain, pain in extremity, splenomegaly, anemia, upper respiratory tract infection, urinary tract infection, epistaxis, chest pain, diarrhea, hypoesthesia, and alopecia

Please see NEUPOGEN® full Prescribing Information.

Indications

Patients with Cancer Receiving Myelosuppressive Chemotherapy
NEUPOGEN® is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.

Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy
NEUPOGEN® is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML).

Patients with Cancer Undergoing Bone Marrow Transplantation
NEUPOGEN® is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g. febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation.



Patients Undergoing Autologous Peripheral Blood Progenitor Cell Collection and Therapy
NEUPOGEN® is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. 



Patients with Severe Chronic Neutropenia
NEUPOGEN® is indicated for chronic administration to reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia.
 

References:

1. Scott SD, Chrischilles EA, Link BK, et al. J Manag Care Pharm. 2003;9(suppl 2):15-21. 2. NEUPOGEN® (filgrastim) prescribing information, Amgen.

Would a once-per-cycle G-CSF be 
appropriate for some of your patients?

syringe-icon

Learn More

Would a once-per-cycle
G-CSF be appropriate for some of your patients?